Redeye maintains its optimistic outlook post the Q1 2024 report despite slightly lower sales and profitability than expected. The surprisingly strong order intake confirms product-market fit and increases the likelihood of significant orders from the European market. Our Base case remains intact at SEK1.4, with considerable upside potential in the share price highlighted.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/